Serum biomarkers for diagnosis and characterization of prostate cancer. / Biomarcadores plasmáticos en el diagnóstico y caracterización del cáncer de próstata.

PSA is the most widely used diagnosticand prognostic biomarker in prostate cancer (PCa).However, its lack of specificity has generated the needto search for new complementary markers. In thisscenario, blood plasma constitutes one of the sourcesof search for new markers, which have been tried tobe combined with PSA and other clinical variables inorder to develop tests that increase their diagnosticspecificity.This narrative review of the literature provides anoverview of commercially available plasma biomarkers and tests for use in different clinical settingsfor PCa. The most studied markers to help select theappropriate patients for initial and / or repeat biopsyhave been: PHI, 4K, STHLM3. These markers havebeen oriented towards the diagnosis of the so-calledclinically signifi cant PCa, trying to validate and calibratetheir algorithms in different populations. Giventhe development and evolution in the diagnosis of PCa,there is still a lack of evidence of the impact of magneticresonance imaging (MRI) when used in combinationwith these new markers, as well as its possiblerole in the screening of the disease and not only in theearly diagnosis process. Furthermore, there are only asmall number of studies that have directly comparedthese tests with each other and with PSA, so there isnot enough evidence to know which test has the bestproperties in each clinical scenario. In order to clarifythe true diagnostic role of these new biomarkers, newprospective, comparative studies in different populationsare absolutely necessary to evaluate their clinicalutility in combination with MRI and fusion biopsy.

El PSA es el biomarcador diagnóstico ypronóstico más ampliamente utilizado en cáncer deprostata (CaP). Sin embargo, su falta de especificidadha generado la necesidad de buscar nuevos marcadorescomplementarios. En este escenario, el plasmasanguíneo constituye una de las fuentes de búsquedade nuevos marcadores, los cuales han tratado decombinarse con el PSA y otras variables clínicas conel objeto de desarrollar tests que aumentaran su especificidaddiagnóstica.En esta revisión narrativa de la literatura se proporcionauna descripción general de los biomarcadoresplasmáticos y tests disponibles comercialmentepara ser utilizados en diferentes contextos clínicosdel CaP. Los test más estudiados para ayudar a seleccionarlos pacientes adecuados para la biopsia inicialy / o repetida han sido: PHI, 4K, STHLM3. Estos testse han orientado hacia el diagnóstico del denominadoCaP clínicamente significativo, intentando validary calibrar sus algoritmos en diferentes poblaciones.Dado el desarrollo y evolución en el diagnóstico deCaP, aún existe una falta de evidencia del impacto de la resonancia magnética (RM) al ser empleada encombinación con estos nuevos marcadores, así comosu posible papel en el screening de la enfermedad yno solo en el proceso de diagnóstico precoz. Además,solo se dispone de una pequeña cantidad de estudiosque hayan comparado directamente estos test entreellos y con el PSA, de modo que no existe evidenciasuficiente para saber qué test tiene mejores propiedadesen cada escenario clínico. En el escenarioactual, para poder aclarar el verdadero papel diagnósticode estos nuevos biomarcadores, son absolutamentenecesarios nuevos estudios prospectivos,comparativos y en diferentes poblaciones, que evalúensu utilidad clínica en combinación con la RM yla biopsia fusión.

Biomarcadores plasmáticos en el diagnóstico y caracterización del cáncer de próstata / Serum biomarkers for diagnosis and characterization of prostate cáncer

El PSA es el biomarcador diagnóstico y pronóstico más ampliamente utilizado en cáncer deprostata (CaP). Sin embargo, su falta de especificidadha generado la necesidad de buscar nuevos marcadores complementarios. En este escenario, el plasmasanguíneo constituye una de las fuentes de búsqueda de nuevos marcadores, los cuales han tratado decombinarse con el PSA y otras variables clínicas conel objeto de desarrollar tests que aumentaran su especificidad diagnóstica.En esta revisión narrativa de la literatura se proporciona una descripción general de los biomarcadores plasmáticos y tests disponibles comercialmentepara ser utilizados en diferentes contextos clínicosdel CaP. Los test más estudiados para ayudar a seleccionar los pacientes adecuados para la biopsia inicialy / o repetida han sido: PHI, 4K, STHLM3. Estos testse han orientado hacia el diagnóstico del denominado CaP clínicamente significativo, intentando validary calibrar sus algoritmos en diferentes poblaciones.Dado el desarrollo y evolución en el diagnóstico deCaP, aún existe una falta de evidencia del impacto de la resonancia magnética (RM) al ser empleada encombinación con estos nuevos marcadores, así comosu posible papel en el screening de la enfermedad yno solo en el proceso de diagnóstico precoz. Además,solo se dispone de una pequeña cantidad de estudiosque hayan comparado directamente estos test entreellos y con el PSA, de modo que no existe evidenciasuficiente para saber qué test tiene mejores propiedades en cada escenario clínico. En el escenarioactual, para poder aclarar el verdadero papel diagnóstico de estos nuevos biomarcadores, son absolutamente necesarios nuevos estudios prospectivos,comparativos y en diferentes poblaciones, que evalúen su utilidad clínica en combinación con la RM yla biopsia fusión. (AU)

PSA is the most widely used diagnosticand prognostic biomarker in prostate cancer (PCa).However, its lack of specificity has generated the needto search for new complementary markers. In thisscenario, blood plasma constitutes one of the sourcesof search for new markers, which have been tried tobe combined with PSA and other clinical variables inorder to develop tests that increase their diagnosticspecificity.This narrative review of the literature provides anoverview of commercially available plasma biomarkers and tests for use in different clinical settingsfor PCa. The most studied markers to help select theappropriate patients for initial and / or repeat biopsyhave been: PHI, 4K, STHLM3. These markers havebeen oriented towards the diagnosis of the so-calledclinically signifi cant PCa, trying to validate and calibrate their algorithms in different populations. Giventhe development and evolution in the diagnosis of PCa,there is still a lack of evidence of the impact of magnetic resonance imaging (MRI) when used in combination with these new markers, as well as its possiblerole in the screening of the disease and not only in theearly diagnosis process. Furthermore, there are only asmall number of studies that have directly comparedthese tests with each other and with PSA, so there isnot enough evidence to know which test has the bestproperties in each clinical scenario. In order to clarifythe true diagnostic role of these new biomarkers, newprospective, comparative studies in different populations are absolutely necessary to evaluate their clinicalutility in combination with MRI and fusion biopsy. (AU)

Predictive role of interleukin-6 and CAT score in mechanical ventilation in patients with chronic obstructive pulmonary disease at the acute exacerbation stage in the emergency department / 世界急诊医学杂志（英文）

@#BACKGROUND: The study aimed to evaluate the predictive role of interleukin-6 (IL-6) and chronic obstructive pulmonary disease (COPD) assessment test (CAT) score in mechanical ventilation (MV) in COPD patients at the acute exacerbation stage in the emergency department (ED). METHODS: For a one-year period, among adult patients in the ED who met the criteria of acute exacerbation of COPD, 158 who received MV within 48 hours after admission were compared to 294 who didn't require MV within the same period after admission. IL-6 level and CAT score were compared between the two groups. The predicted value of IL-6 and CAT score was assessed by logistic regression analysis and a receiver operating characteristic (ROC) curve. RESULTS: The IL-6 and CAT scores in the 158 MV patients were much higher than those without. IL-6 and CAT scores were independent predictors of MV within 48 hours using logistic regression analysis (IL-6: odds ratio [OR] 1.053, 95% confidence interval [CI] 1.039–1.067, P<0.001; CAT score: OR 1.122, 95% CI 1.086–1.159, P<0.001). The combination of IL-6 and CAT scores (area under ROC curve [AUC] 0.826, 95% CI 0.786–0.866, P<0.001) improved the accuracy of predicting MV within 48 hours when compared with IL-6 (AUC 0.752, 95% CI 0.703–0.800, P<0.001) and CAT scores alone (AUC 0.739, 95% CI 0.692–0.786, P<0.001). The sensitivity and specificity were 69.6%, 74.1%, 75.32% and 63.6%, respectively. CONCLUSION: The combined of IL-6 and CAT scores is useful for evaluating the risk of COPD patients at acute exacerbation in ED, and can provide a predictive value for MV or not within 48 hours.

Clinical observation of Qingre-Jiangni-Zhixue decoction combined with omeprazole sodium in the treatment of acute nonvariceal upper gastrointestinal hemorrhage / 国际中医中药杂志

Objective To observe the clinical effect of Qingre-Jiangni-Zhixue decoction combined with omeprazole sodium on acute non-variceal upper gastrointestinal bleeding. Methods A total of 64 patients with acute non-variceal upper gastrointestinal bleeding were divided into the observation group and control group according to random number table method, with 32 cases in each group. The control group was given the routine clinical treatment combined with omeprazole sodium, and the observation group was given Qingre-Jiangni-Zhixue decoction on the basis of the control group. After 7 days of continuous treatment, the basic clinical indexes (hemostasis time, blood transfusion volume, hospitalization time, 72 hours hemostasis rate, rebleeding rate), oxidative stress indexes (cortisol, malondialdehyde, antidiuretic hormone, blood glucose) and serum inflammatory factors (hs-CRP, TNF-α, IL-1β) were observed before and after treatment, and the clinical efficacy were evaluated. Results The total effective rate of the observation group was 90.6% (29/32), which was significantly higher than that of the control group 71.9% (23/32), with statistically significant (χ2=4.730, P=0.029). After treatment, the hemostasis time (18.86 ± 2.97 h vs. 29.12 ± 4.07 h, t=7.354),blood transfusion volume (559.32 ± 67.17 ml vs. 612.73 ± 75.81 ml, t=11.032),hospitalization time (5.43 ± 0.67 d vs. 9.26 ± 1.15 d, t=5.871) of the observation group were significantly lower than those of the control group (P<0.05). The 72 h hemostasis rate of the observation group was 3.1%, which was significantly lower than that of the control group 21.9%, with statistically significant (χ2=5.143, P<0.05). The rebleeding rate of the observation group was 96.9%, which was significantly higher than that of the control group 81.3% (χ2=4.010, P=0.045). After treatment, the cortisol level, the malondialdehyde level, blood glucose, antidiuretic hormone of the observation group were lower than those of the control group (t were 8.106, 4.976, 4.842, 5.093, all Ps<0.01). After treatment, the hs-CRP, serum TNF-α, serum IL-1β of the observation group were lower than those of the control group (t were 5.506, 4.983, 7.962, all Ps<0.01). Conclusions The application of Qingre-Jiangni-Zhixue decoction combined with omeprazole sodium can inhibit the expression of serum inflammatory cytokines in patients with acute non-variceal upper gastrointestinal bleeding, reduce the oxidative stress injury caused by bleeding, and improve the hemostatic efficiency.

Analysis of effi cacy of treatment in 141 patients with high-risk acute upper gastrointestinal bleeding / 中华急诊医学杂志

Objective To retrospectively analyze the emergency treatment in 141 patients with high-risk of acute upper gastrointestinal bleeding(AUGIB) in order to improve the effi cacy of treatment. In addition, to evaluate the predictive values in accuracy terms of AIMS65, Glasgow-Blachford(GBS) and Pre-Rockall scores for risk stratifi cation in AUGIB by comparison among them. Methods Data of 141 patients with AUGIB admitted from Nov.1,2013 to May 31,2017 in our emergency department(ED) were retrospectively analyzed. All patients at fi rst were treated with pharmacologic therapy in emergency room, and some of them underwent endoscopic remedy, intervention or surgery as a last resort. The scores of AIMS65, Glasgow-Blachford(GBS) and Pre-Rockall scores were calculated respectively, and the in-hospital 30-day death and re-bleeding were taken as the study endpoints. Comparison of clinical value among the three scores was carried out by plotting their ROC and calculating the AUC. Results Of them, 65.25% patients underwent endoscopy, and the leading cause of bleeding was peptic ulcer (64.12%). Endoscopic hemostatic clips were used in 8 cases, endoscopic sclerotic therapy in 4 cases, balloon tamponade in 4 cases, TEA (therapeutic embolization approach) in 9 cases, TIPS (trans-internal jugular vein for making hepatic portal vein shunt by stent) in 3 cases, and surgical intervention in 2 cases. Re-bleeding rate was 14.18%, death rate 11.35%. AIMS65 and Pre-Rockall were better than GBS in predicting in-hospital 30-day mortality. There was no difference in predicting re-bleeding among these three scores. Conclusions Medicines combined with endoscopy, various interventions and surgical operation can effectively treat high-risk patients with AUGIB. Both AIMS65 and Pre-Rockall are able to predict mortality accurately with easy practice. Both are suitable in ED to stratify the risk of AUGIB.

Prediction of Outcome of In-Hospital Mortality for Acute Heart Failure.

BACKGROUND: Prediction of in-hospital mortality in acute heart failure (AHF) is sought to evaluate the blood pressure and renal function. Acute heart failure with systolic pressure and impaired renal function is common but not well understood. METHODS: We reviewed 187 patients with acute heart failure from 2013-2014. Then we apply validation of a risk stratification tool to predict in-hospital mortality for acute HF group. The analysis of the inhospital mortality with acute heart failure group will based on BUN level, systolic blood pressure, and serum creatinine level. RESULTS: There were 23 patients in the in-hospital mortality group and 164 patients in the survived group after hospitalization. The 3 physiological parameters were compared between in-hospital mortality and survival group from the validation of a risk stratification tool: systolic blood pressure (123.7 ± 30.1 vs. 143.7 ± 34.2 mmHg, p value = 0.009), blood urea nitrogen (57.2 ± 27.7 vs. 38.7 ± 24.7 mg/dL, p value = 0.001), serum creatinine (2.38 ± 1.91 vs. 2.06 ± 1.62 mg/dL, p value = 0.390). Finding from NTUH compared with ADHERE was the group with blood urea nitrogen 43 mg/dL, systolic BP < 115 mmHg, and serum creatinine < 2.75 mg/dL will be high risk of in-hospital mortality (50% in NTUH vs. 12.42% in ADHERE). In our validation of a risk stratification tool, the accuracy was 77.8 % by receiver operator characteristic curve analysis. CONCLUSION: On the basis of these 3 variables- BUN level, systolic blood pressure, and serum creatinine level from the current analysis, the acute heart failure patient can be readily stratified into groups at high risk for in-hospital mortality.